ADMA Biologics announced that it has received U.S. Food and Drug Administration, FDA, approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland. This plasma collection facility commenced operations and initiated source plasma collection in the first half of 2023. With the FDA approval announced today, this facility is now licensed to introduce into interstate commerce human source plasma for further manufacturing in the U.S. “The successful expansion of ADMA’s plasma collection network accomplishes the Company’s goal of plasma supply self-sufficiency, supports ongoing revenue growth objectives, and further enhances ADMA’s profitability outlook. The approval is a testament to the BioCenters team’s tireless commitment, and we thank the FDA for its efforts and expeditious review of the Laurel, MD Biologics License Application,” said Adam Grossman, President and Chief Executive Officer of ADMA.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ADMA:
- ADMA BioCenters Receives FDA Approval for its Tenth Plasma Collection Center, Located in Laurel, MD
- ADMA Biologics boosts FY23 revenue view to exceed $250M from $240M previously
- ADMA Biologics reports Q3 EPS 1c, consensus 1c
- ADMA Upcoming Earnings Report: What to Expect?
- ADMA Biologics to Report Third Quarter 2023 Financial Results on November 8, 2023